2018
Total Awards
$837.6M

2009-2018
Sponsored Awards

HHS  $283.0M
USDA  $74.3M
NSF   $55.2M
DOD   $49.2M
Education $24.9M
VA    $15.4M
Energy $14.9M
DOT   $12.0M
Commerce $9.1M
USAID $5.9M
NASA  $5.7M
Justice $4.0M
Interior $3.3M
Other $2.4M
EPA   $1.3M
*amounts rounded

2018 AWARDS
BY SPONSOR

$128.6M
FOUNDATIONS

$61.1M
INDUSTRY

$55.1M
STATE/LOCAL

$32.2M
OTHER
2018 AWARDS BY ACADEMIC UNIT

- $348.8M COLLEGE OF MEDICINE
- $166.2M UF/IFAS
- $85.3M COLLEGE OF ENGINEERING
- $39.9M COLLEGE OF LIBERAL ARTS & SCIENCES
- $197.4M OTHER

R&D Expenditures at Public Institutions
(SOURCE: NATIONAL SCIENCE FOUNDATION, FY 2017)

1. University of Michigan $1.53B
2. University of California, San Francisco $1.41B
3. University of Washington $1.35B
4. University of Wisconsin $1.19B
5. University of California, San Diego $1.13B
6. University of North Carolina, Chapel Hill $1.10B
7. University of California, Los Angeles $1.08B
8. University of Pittsburgh $939.7M
9. University of Minnesota $921.7M
10. Texas A&M University $905.5M
11. M. D. Anderson Cancer Center $888.0M
12. Ohio State University $864.3M
13. Penn State University $854.8M
14. Georgia Institute of Technology $804.3M
15. University of Florida $801.4M
16. University of California, Berkeley $770.8M
17. University of California, Davis $738.3M
18. Michigan State University $694.9M
19. Rutgers University $681.7M
20. University of Texas $652.2M

2018 LICENSES/OPTIONS
226*
*Includes all UF license and option agreements, including those by OTL and the UF Institute of Food and Agricultural Sciences (UF/IFAS)

Transferring University of Florida discoveries from the laboratory to the market

2018 UF INNOVATE
A team led by Dr. Nancy Mendenhall, medical director of the UF Health Proton Therapy Institute, received an $11.5 million award from the nonprofit Patient-Centered Outcomes Research Institute, or PCORI, to compare the effectiveness of traditional radiation treatment and proton therapy for prostate cancer, a leading cause of cancer death in men in the United States. The project will compare 1,500 patients treated with proton therapy with 1,500 patients treated with traditional radiation therapy at 42 treatment centers across the United States.

At the University of Florida, one mission drives all of our research and scholarly activities — to make a difference in the state, the nation and the world through the discovery of new knowledge and the translation of this knowledge to impact, all within a framework that educates and develops the next generation of discoverers, thinkers and doers.

Over the past five years, with the support of its Board of Trustees and the Florida Legislature, UF has been able to add hundreds of new researchers to its already world-class faculty, deepening our bench of scientists and scholars.

In 2018, those faculty members attracted a record $837.6 million in funding from government agencies, industry and private foundations. This shattered our previous record set in fiscal year 2016 by $113.6 million.

These funds are the fuel that enables our faculty to conduct research that results in new knowledge, new treatments and new technologies. With one of the largest, most diverse research portfolios in the nation, UF offers unprecedented opportunities for researchers from medicine to agriculture, and engineering to the social sciences to collaborate on discoveries at the leading edge of knowledge.

The professionals at UF Innovate — the umbrella organization for our Tech Licensing and Ventures offices and two business incubators, The Hub and Sid Martin Biotech — work with faculty as research moves along the continuum from idea to impact to identify discoveries with commercial potential. UF Innovate connects innovators with entrepreneurs, investors and industry, incubates startups and growth companies, and fosters a resilient economy — all in an effort to make the world a better place.
Electrical and computer engineering Professor Alina Zare received a $6 million award from the U.S. Department of Energy Advanced Research Projects Agency, or ARPA-E, to research ways to use backscatter X-rays to more efficiently analyze switchgrass roots for carbon sequestration traits. Zare is collaborating with materials science and engineering Professor Jim Baciak to adapt a backscatter X-ray technology he developed for the railroad industry to be used on farm equipment to enable high-resolution imaging of plant roots — without disrupting plants or soil.

Animal science Professor Adegbola Adesogan, director of UF/IFAS’ Feed the Future Innovation Lab, received an $8.7 million grant from the Bill & Melinda Gates Foundation to fund research aimed at tackling global hunger by helping small farmers more effectively manage livestock in Ethiopia and Burkina Faso. Another component of the research in Ethiopia will focus on helping children under the age of 2 avoid chronic gut inflammation by limiting exposure to chicken droppings. An estimated 40 percent of all children under 5 in Ethiopia suffer from malnutrition and stunting that is likely related to the gut inflammation.
Psychology Professor Dorothy Espelage received a $1 million grant from the National Institute of Justice to implement a pilot anti-violence program for school resource officers in Miami-Dade Public Schools. Over the next three years, the team will work with at least 140 school resource officers who will, in turn, positively impact over 133,000 students in Miami-Dade County Public Schools.

Brammer Bio, a leader in the development and production of specialized drugs for the gene therapy industry, grew out of the state-funded UF Center of Excellence for Regenerative Health Biotechnology and Florida Biologix. Today, Brammer Bio is expanding rapidly at its Alachua facilities about 15 miles north of UF, where more than 250 employees are manufacturing small doses of new treatments for clinical trials.
In 2018, the U.S. Food and Drug Administration approved Luxturna, a gene therapy treatment for blindness that has been under development in a collaboration between scientists at UF and other institutions for decades. Luxturna is the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene.